WO2024254540A3 - Traitement de la sclérose latérale amyotrophique avec composition de vésicules extracellulaires - Google Patents

Traitement de la sclérose latérale amyotrophique avec composition de vésicules extracellulaires Download PDF

Info

Publication number
WO2024254540A3
WO2024254540A3 PCT/US2024/033123 US2024033123W WO2024254540A3 WO 2024254540 A3 WO2024254540 A3 WO 2024254540A3 US 2024033123 W US2024033123 W US 2024033123W WO 2024254540 A3 WO2024254540 A3 WO 2024254540A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
treatment
extracellular vesicle
vesicle composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033123
Other languages
English (en)
Other versions
WO2024254540A2 (fr
Inventor
Timothy Alexander Moseley
Kenneth Allen PETTINE
Joshua J. CROSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Direct Biologics LLC
Original Assignee
Direct Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics LLC filed Critical Direct Biologics LLC
Priority to CN202480051907.2A priority Critical patent/CN121729236A/zh
Publication of WO2024254540A2 publication Critical patent/WO2024254540A2/fr
Publication of WO2024254540A3 publication Critical patent/WO2024254540A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sont divulguées des méthodes de traitement de la sclérose latérale amyotrophique chez un sujet par administration d'un produit de sécrétome de CSM thérapeutique fabriqué par un procédé comprenant la culture de CSM dérivées de moelle osseuse dans des conditions qui comprennent une tension d'oxygène inférieure à 5 % et un milieu de culture doté d'un pH inférieur à 7.
PCT/US2024/033123 2023-06-09 2024-06-07 Traitement de la sclérose latérale amyotrophique avec composition de vésicules extracellulaires Pending WO2024254540A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480051907.2A CN121729236A (zh) 2023-06-09 2024-06-07 使用细胞外囊泡组合物的肌萎缩性侧索硬化症治疗

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363507204P 2023-06-09 2023-06-09
US63/507,204 2023-06-09
US202463570632P 2024-03-27 2024-03-27
US63/570,632 2024-03-27

Publications (2)

Publication Number Publication Date
WO2024254540A2 WO2024254540A2 (fr) 2024-12-12
WO2024254540A3 true WO2024254540A3 (fr) 2025-02-20

Family

ID=93796466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033123 Pending WO2024254540A2 (fr) 2023-06-09 2024-06-07 Traitement de la sclérose latérale amyotrophique avec composition de vésicules extracellulaires

Country Status (2)

Country Link
CN (1) CN121729236A (fr)
WO (1) WO2024254540A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3920946A4 (fr) 2019-02-07 2022-11-09 Direct Biologics LLC Procédé de traitement de l'arthrose au moyen d'une combinaison d'exosomes de cellules souches mésenchymateuses, de cellules souches mésenchymateuses synoviales et d'échafaudages
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269739A1 (en) * 2016-11-03 2019-09-05 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
US20200316226A1 (en) * 2017-12-20 2020-10-08 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US20210128627A1 (en) * 2016-07-18 2021-05-06 Brainstorm Cell Therapeutics Ltd. Methods for treating amyotrophic lateral sclerosis (als)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210128627A1 (en) * 2016-07-18 2021-05-06 Brainstorm Cell Therapeutics Ltd. Methods for treating amyotrophic lateral sclerosis (als)
US20190269739A1 (en) * 2016-11-03 2019-09-05 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
US20200316226A1 (en) * 2017-12-20 2020-10-08 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery

Also Published As

Publication number Publication date
CN121729236A (zh) 2026-03-24
WO2024254540A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024254540A3 (fr) Traitement de la sclérose latérale amyotrophique avec composition de vésicules extracellulaires
WO2024254459A3 (fr) Traitement du syndrome douloureux régional complexe avec une composition de vésicules extracellulaires
CN113041184B (zh) 一种洗发香波及其制备方法
CA3063540A1 (fr) Compositions et procedes pour prevenir, ralentir et inverser le vieillissement de la peau
KR101425716B1 (ko) 신규의 락토바실러스 퍼멘텀 균주, 이를 이용한 화장료 조성물 및 그 제조방법
ATE270323T1 (de) Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
ZA200900444B (en) Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same
WO2025189128A8 (fr) Traitement de l'infertilité avec une composition de vésicule extracellulaire
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
BR112014028551A2 (pt) meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
IL317920A (en) Method for producing a cerebral infarction model in non-human primate animals and a pharmaceutical composition for treating cerebral infarction
JP7297021B2 (ja) 乳酸菌発酵産物含有外傷外用組成物
CN104490727B (zh) 一种干细胞与玻尿酸的组合物与应用
WO2023007244A1 (fr) Population de cellules de mammifère utile en thérapie cellulaire
US10842735B2 (en) Hair growth-promoting composition
KR102588400B1 (ko) 면역 질환의 예방 또는 치료용 중간엽줄기세포 배양액 및 이의 제조방법
CN117535237A (zh) 人脐带间充质干细胞培养基及其制备方法
CN105168092A (zh) 具有保湿美白功能的洁面组合物及其制备方法
WO2023067394A3 (fr) Procédés de fabrication de vésicules extracellulaires, et compositions et procédés d'utilisation de celles-ci
WO1996017627A3 (fr) Systeme destine a l'entretien, la croissance et la differentiation de cellules de moelle osseuse pluripotentes souches, parentes et a maturite, d'origine humaine ou provenant de primates
WO2003072128A8 (fr) Procedes et composes destines a traiter des defauts osseux ou du cartilage
MX2025003509A (es) Medios condicionados derivados del foliculo piloso humano y metodos para fabricar los mismos
WO2025133708A2 (fr) Utilisation thérapeutique de compositions et procédés de traitement épidermique
CN121337857A (zh) 发酵乳杆菌gkf3用于制备促进皮肤伤口愈合及抗氧化的局部组合物的用途
CN117503679A (zh) 用于美容治疗的干细胞组合物及试剂盒

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820188

Country of ref document: EP

Kind code of ref document: A2

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820188

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024820188

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109

ENP Entry into the national phase

Ref document number: 2024820188

Country of ref document: EP

Effective date: 20260109